{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T13:58:34Z","timestamp":1777039114184,"version":"3.51.4"},"reference-count":76,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","clinicalkey.com.au","clinicalkey.fr","liver.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.cld.2015.08.006","type":"journal-article","created":{"date-parts":[[2015,11,20]],"date-time":"2015-11-20T20:42:44Z","timestamp":1448052164000},"page":"113-130","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Novel Therapies on Primary Biliary Cirrhosis"],"prefix":"10.1016","volume":"20","author":[{"given":"Frank","family":"Czul","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia","family":"Levy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cld.2015.08.006_bib1","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1055\/s-0034-1383733","article-title":"Old and novel therapies for primary biliary cirrhosis","volume":"34","author":"Pares","year":"2014","journal-title":"Semin Liver Dis"},{"issue":"5","key":"10.1016\/j.cld.2015.08.006_bib2","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/01.mcg.0000225653.07932.8f","article-title":"Clinical epidemiology of primary biliary cirrhosis: incidence, prevalence, and impact of therapy","volume":"41","author":"Lazaridis","year":"2007","journal-title":"J\u00a0Clin Gastroenterol"},{"issue":"2","key":"10.1016\/j.cld.2015.08.006_bib3","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1053\/j.gastro.2004.05.005","article-title":"Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment","volume":"127","author":"Selmi","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2015.08.006_bib4","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/hep.22906","article-title":"Primary biliary cirrhosis","volume":"50","author":"Lindor","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2015.08.006_bib5","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3350\/kjhep.2011.17.3.173","article-title":"The diagnosis and treatment of primary biliary cirrhosis","volume":"17","author":"Kim","year":"2011","journal-title":"Korean J Hepatol"},{"key":"10.1016\/j.cld.2015.08.006_bib6","unstructured":"European Association for the Study of Liver Diseases (EASL). Clinical practice guidelines. Primary biliary cirrhosis. Available at: http:\/\/www.easl.eu\/research\/our-contributions\/clinical-practice-guidelines\/detail\/management-of-cholestatic-liver-diseases\/report\/3. Accessed June 22, 2015."},{"issue":"2","key":"10.1016\/j.cld.2015.08.006_bib7","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.cld.2012.12.003","article-title":"Primary biliary cirrhosis: therapeutic advances","volume":"17","author":"Czul","year":"2013","journal-title":"Clin Liver Dis"},{"issue":"6","key":"10.1016\/j.cld.2015.08.006_bib8","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/ncpgasthep0521","article-title":"Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis","volume":"3","author":"Beuers","year":"2006","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"issue":"Suppl 1","key":"10.1016\/j.cld.2015.08.006_bib9","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S2210-7401(12)70015-3","article-title":"Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action","volume":"36","author":"Poupon","year":"2012","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"5","key":"10.1016\/j.cld.2015.08.006_bib10","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S0168-8278(99)80136-6","article-title":"Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial","volume":"30","author":"Angulo","year":"1999","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2015.08.006_bib11","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/hep.22831","article-title":"Treatment with immunosuppressives in patients with primary biliary cirrhosis who fail to respond to ursodiol","volume":"50","author":"Kaplan","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2015.08.006_bib12","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/hep.26322","article-title":"Early biochemical response to ursodeoxycholic acid and long-term prognosis of primary biliary cirrhosis: results of a 14-year cohort study","volume":"58","author":"Zhang","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2015.08.006_bib13","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","article-title":"Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid","volume":"130","author":"Pares","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2015.08.006_bib14","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/hep.22428","article-title":"Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis","volume":"48","author":"Corpechot","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2015.08.006_bib15","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1053\/j.gastro.2009.01.003","article-title":"Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid","volume":"136","author":"Kuiper","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2015.08.006_bib16","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/ajg.2010.216","article-title":"Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis","volume":"105","author":"Kumagi","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2015.08.006_bib17","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1872-034X.2011.00782.x","article-title":"Biochemical response to ursodeoxycholic acid predicts long-term outcome in Japanese patients with primary biliary cirrhosis","volume":"41","author":"Azemoto","year":"2011","journal-title":"Hepatol Res"},{"key":"10.1016\/j.cld.2015.08.006_bib18","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1478-3231.1999.tb00020.x","article-title":"Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid","volume":"19","author":"Angulo","year":"1999","journal-title":"Liver"},{"key":"10.1016\/j.cld.2015.08.006_bib19","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2014.08.029","article-title":"Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study","volume":"147","author":"Lammers","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2015.08.006_bib20","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1021\/jm025529g","article-title":"6 alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity","volume":"45","author":"Pelliciari","year":"2002","journal-title":"J\u00a0Med Chem"},{"issue":"4","key":"10.1016\/j.cld.2015.08.006_bib21","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1136\/gut.2010.212159","article-title":"Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease","volume":"60","author":"Gadaleta","year":"2011","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.cld.2015.08.006_bib22","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.gastro.2014.12.005","article-title":"Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid","volume":"148","author":"Hirschfield","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2015.08.006_bib23","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S0168-8278(11)60030-5","article-title":"An international study evaluating the farnesoid X receptor agonist obeticholic acid as monotherapy in PBC","volume":"54","author":"Kowdley","year":"2011","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2015.08.006_bib24","doi-asserted-by":"crossref","first-page":"S525","DOI":"10.1016\/S0168-8278(14)61463-X","article-title":"The first primary biliary cirrhosis phase 3 trial in two decades\u2014an international study of the FXR agonist obeticholic acid in PBC patients","volume":"60","author":"Nevens","year":"2014","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2015.08.006_bib25","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3748\/wjg.v10.i6.894","article-title":"Fenofibrate for patients with asymptomatic primary biliary cirrhosis","volume":"10","author":"Dohmen","year":"2004","journal-title":"World J Gastroenterol"},{"issue":"5","key":"10.1016\/j.cld.2015.08.006_bib26","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1002\/hep.26018","article-title":"Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid","volume":"57","author":"Honda","year":"2013","journal-title":"Hepatology"},{"issue":"Suppl 3","key":"10.1016\/j.cld.2015.08.006_bib27","doi-asserted-by":"crossref","first-page":"S515","DOI":"10.1111\/j.1872-034X.2007.00232.x","article-title":"Fibrate for treatment of primary biliary cirrhosis","volume":"37","author":"Iwasaki","year":"2007","journal-title":"Hepatol Res"},{"issue":"10","key":"10.1016\/j.cld.2015.08.006_bib28","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1111\/j.1572-0241.2000.03220.x","article-title":"Bezafibrate in the treatment of primary biliary cirrhosis: comparison with ursodeoxycholic acid","volume":"95","author":"Kurihara","year":"2000","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.cld.2015.08.006_bib29","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00535-002-1102-7","article-title":"Bezafibrate treatment: a new medical approach for PBC patients","volume":"38","author":"Kanda","year":"2003","journal-title":"J\u00a0Gastroenterol"},{"issue":"2","key":"10.1016\/j.cld.2015.08.006_bib30","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00535-004-1518-3","article-title":"Therapeutic efficacy of decreased nitrite production by bezafibrate in patients with primary biliary cirrhosis","volume":"40","author":"Akbar","year":"2005","journal-title":"J\u00a0Gastroenterol"},{"issue":"7","key":"10.1016\/j.cld.2015.08.006_bib31","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1007\/s00535-006-1831-0","article-title":"Bezafibrate may attenuate biliary damage associated with chronic liver diseases accompanied by high serum biliary enzyme levels","volume":"41","author":"Kita","year":"2006","journal-title":"J\u00a0Gastroenterol"},{"issue":"1","key":"10.1016\/j.cld.2015.08.006_bib32","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1572-0241.2000.01667.x","article-title":"Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: a preliminary study","volume":"95","author":"Nakai","year":"2000","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.cld.2015.08.006_bib33","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/MCG.0b013e3181c115b3","article-title":"Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid","volume":"44","author":"Hazzan","year":"2010","journal-title":"J\u00a0Clin Gastroenterol"},{"issue":"2","key":"10.1016\/j.cld.2015.08.006_bib34","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/liv.12290","article-title":"Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid","volume":"34","author":"Lens","year":"2014","journal-title":"Liver Int"},{"key":"10.1016\/j.cld.2015.08.006_bib35","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1872-034X.2007.00305.x","article-title":"The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: a prospective, multicenter study","volume":"38","author":"Iwasaki","year":"2008","journal-title":"Hepatol Res"},{"key":"10.1016\/j.cld.2015.08.006_bib36","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.hepres.2004.04.001","article-title":"Prospective randomized crossover trial of combination therapy with bezafibrate and UDCA for primary biliary cirrhosis","volume":"29","author":"Itakura","year":"2004","journal-title":"Hepatol Res"},{"key":"10.1016\/j.cld.2015.08.006_bib37","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s00535-006-1778-1","article-title":"Long-term effect of bezafibrate on parameters of hepatic fibrosis in primary biliary cirrhosis","volume":"41","author":"Ohmoto","year":"2006","journal-title":"J\u00a0Gastroenterol"},{"issue":"8","key":"10.1016\/j.cld.2015.08.006_bib38","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1111\/j.1572-0241.2002.05944.x","article-title":"Fenofibrate treatment in patients with primary biliary cirrhosis","volume":"97","author":"Ohira","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2015.08.006_bib39","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2174\/1874192401004010120","article-title":"Fenofibrate in primary biliary cirrhosis: a pilot study","volume":"4","author":"Liberopoulos","year":"2010","journal-title":"Open Cardiovasc Med J"},{"issue":"2","key":"10.1016\/j.cld.2015.08.006_bib40","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2036.2010.04512.x","article-title":"Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid","volume":"33","author":"Levy","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.cld.2015.08.006_bib41","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/hep.22670","article-title":"Comment on biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis","volume":"49","author":"Walker","year":"2009","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2015.08.006_bib42","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.clinre.2015.02.011","article-title":"Fenofibrate is effective adjunctive therapy in the treatment of primary biliary cirrhosis: a meta-analysis","volume":"39","author":"Grigorian","year":"2015","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.cld.2015.08.006_bib43","doi-asserted-by":"crossref","first-page":"S387","DOI":"10.1016\/S0168-8278(13)60941-1","article-title":"Who may have treatment benefits with fibrates in primary biliary cirrhosis: a single center retrospective observational cohort analysis","volume":"58","author":"Komori","year":"2013","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2015.08.006_bib44","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/ajg.2015.20","article-title":"A\u00a0prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia","volume":"110","author":"Hosonuma","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2015.08.006_bib45","first-page":"219","article-title":"Efficacy of fenofibrate in Chinese patients with primary biliary cirrhosis partially responding to ursodeoxycholic acid therapy","volume":"13","author":"Han","year":"2012","journal-title":"J\u00a0Dig Dis"},{"key":"10.1016\/j.cld.2015.08.006_bib46","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0016-5085(19)32419-9","article-title":"Effects of clofibrate in primary biliary cirrhosis hypercholesterolemia and gallstones","volume":"69","author":"Summerfield","year":"1975","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2015.08.006_bib47","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0016-5085(19)33896-X","article-title":"Paradoxical elevation of serum cholesterol by clofibrate in patients with primary biliary cirrhosis","volume":"57","author":"Schaffner","year":"1969","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.cld.2015.08.006_bib48","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0168-8278(96)80327-8","article-title":"Ursodeoxycolic acid and prednisolone versus ursodeoxycholic acid and placebo in the treatment of early stages of primary biliary cirrhosis","volume":"25","author":"Leuschner","year":"1996","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2015.08.006_bib49","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/hep.1840100405","article-title":"A\u00a0pilot, double blinded, controlled 1-year trial of prednisolone treatment in PBC","volume":"10","author":"Mitchison","year":"1989","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2015.08.006_bib50","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S0016-5085(99)70351-3","article-title":"Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial","volume":"117","author":"Leuschner","year":"1999","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.cld.2015.08.006_bib51","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/hep.20646","article-title":"Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial","volume":"41","author":"Rautiainen","year":"2005","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2015.08.006_bib52","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.510310209","article-title":"Oral budesonide in the treatment of patients with primary biliary cirrhosis with suboptimal response to ursodeoxycholic acid","volume":"31","author":"Angulo","year":"2000","journal-title":"Hepatology"},{"issue":"4\u20135","key":"10.1016\/j.cld.2015.08.006_bib53","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.gcb.2010.02.004","article-title":"Triple therapy with ursodeoxycholic acid, budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone","volume":"34","author":"Rabahi","year":"2010","journal-title":"Gastroenterol Clin Biol"},{"issue":"1","key":"10.1016\/j.cld.2015.08.006_bib54","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1053\/jhep.2003.50266","article-title":"Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis","volume":"38","author":"Hempfling","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2015.08.006_bib55","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in\u00a0vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.cld.2015.08.006_bib56","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1155\/2013\/512624","article-title":"Rituximab for the treatment of patients with autoimmune hepatitis who are refractory to or intolerant of standard therapy","volume":"27","author":"Burak","year":"2013","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.cld.2015.08.006_bib57","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/hep.24748","article-title":"Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid","volume":"55","author":"Tsuda","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2015.08.006_bib58","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/ajg.2013.51","article-title":"B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid","volume":"108","author":"Myers","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2015.08.006_bib59","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/ng.627","article-title":"Genome wide meta-analyses identify three loci associated with primary biliary cirrhosis","volume":"42","author":"Liu","year":"2010","journal-title":"Nat Genet"},{"key":"10.1016\/j.cld.2015.08.006_bib60","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/ng.789","article-title":"Genome-wide association identifies 12 new susceptibility loci for primary biliary cirrhosis","volume":"43","author":"Mells","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.cld.2015.08.006_bib61","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1056\/NEJMoa0810440","article-title":"Primary biliary cirrhosis associated with HLA, IL12A and IL 12RB2 variants","volume":"360","author":"Hirshfield","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cld.2015.08.006_bib62","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.jhep.2011.05.040","article-title":"Towards common denominators in primary biliary cirrhosis: the role of IL-12","volume":"56","author":"Lleo","year":"2012","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2015.08.006_bib63","doi-asserted-by":"crossref","first-page":"S189","DOI":"10.1016\/S0168-8278(14)60529-8","article-title":"Phase 2 study evaluating the efficacy and safety of ustekunumab in patients with primary biliary cirrhosis who had an inadequate response to ursodeoxycholic acid","volume":"60","author":"Hirschfield","year":"2014","journal-title":"J\u00a0Hepatol"},{"issue":"2\u20133","key":"10.1016\/j.cld.2015.08.006_bib64","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12016-014-8456-5","article-title":"New therapies for primary biliary cirrhosis","volume":"48","author":"Floreani","year":"2015","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.cld.2015.08.006_bib65","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S1074-7613(02)00362-X","article-title":"The interaction properties of co-stimulatory molecules revisited","volume":"17","author":"Collins","year":"2002","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.cld.2015.08.006_bib66","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nrd1989","article-title":"Abatacept","volume":"5","author":"Moreland","year":"2006","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"10.1016\/j.cld.2015.08.006_bib67","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.autrev.2013.10.010","article-title":"Chemokine (C-X-C motif) ligand (CXCL) 10 in autoimmune diseases","volume":"13","author":"Antonelli","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.cld.2015.08.006_bib68","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jaut.2005.08.009","article-title":"Increased levels of chemokine receptor CXCR3 and chemokines IP-10 and MIG in patients with primary biliary cirrhosis and their first degree relatives","volume":"25","author":"Chuang","year":"2005","journal-title":"J\u00a0Autoimmun"},{"issue":"3","key":"10.1016\/j.cld.2015.08.006_bib69","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1136\/gutjnl-2012-303424","article-title":"Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomized study","volume":"63","author":"Mayer","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.cld.2015.08.006_bib70","first-page":"71","article-title":"Mesenchymal stromal cells multipotency and plasticity: induction toward the hepatic lineage","volume":"13","author":"Saulnier","year":"2009","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"4","key":"10.1016\/j.cld.2015.08.006_bib71","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1182\/blood-2004-04-1559","article-title":"Human mesenchymal stem cells modulate allogeneic immune cell responses","volume":"105","author":"Aggarwal","year":"2005","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cld.2015.08.006_bib72","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s10238-010-0105-6","article-title":"Effect of allogeneic bone marrow\u2013derived mesenchymal stem cells transplantation in a polyI: C-induced primary biliary cirrhosis mouse model","volume":"11","author":"Wang","year":"2011","journal-title":"Clin Exp Med"},{"issue":"Suppl 1","key":"10.1016\/j.cld.2015.08.006_bib73","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/jgh.12029","article-title":"Pilot study of umbilical cord-derived mesenchymal stem cell transfusion in patients with primary biliary cirrhosis","volume":"28","author":"Wang","year":"2013","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"6\u20137","key":"10.1016\/j.cld.2015.08.006_bib74","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.gcb.2010.04.014","article-title":"Linking human beta retrovirus infection with primary biliary cirrhosis","volume":"34","author":"Mason","year":"2010","journal-title":"Gastroenterol Clin Biol"},{"issue":"12","key":"10.1016\/j.cld.2015.08.006_bib75","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1111\/j.1572-0241.2004.40741.x","article-title":"Pilot studies of single and combination antiretroviral therapy in patients with primary biliary cirrhosis","volume":"99","author":"Mason","year":"2004","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"10.1016\/j.cld.2015.08.006_bib76","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/j.1365-2036.2008.03799.x","article-title":"Clinical trial: randomized controlled trial of zidovudine and lamivudine for patients with primary biliary cirrhosis stabilized on ursodiol","volume":"28","author":"Mason","year":"2008","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326115000781?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326115000781?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T18:27:09Z","timestamp":1653589629000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326115000781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":76,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S1089326115000781"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2015.08.006","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel Therapies on Primary Biliary Cirrhosis","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2015.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}